首页> 外文期刊>Archives of Endocrinology and Metabolism >Serum irisin and apelin levels and markers of atherosclerosis in patients with subclinical hypothyroidism
【24h】

Serum irisin and apelin levels and markers of atherosclerosis in patients with subclinical hypothyroidism

机译:亚临床甲状腺功能减退症患者的血清鸢尾素和apelin水平及动脉粥样硬化的标志物

获取原文
获取外文期刊封面目录资料

摘要

Objective: In this study, we aimed to evaluate serum irisin and apelin levels in patients with subclinical hypothyroidism (SCH) when they were subclinical hypothyroid and become euthyroid after levothyroxine therapy and association of these adipokines with markers of atherosclerosis such as serum homocysteine levels and carotid intima-media thickness (IMT). Subjects and methods: The study included 160 patients with newly diagnosed subclinical hypothyroidism due to Hashimoto's thyroiditis and 86 euthyroid healty subjects. Serum glucose and lipid profile, insulin, HOMA, TSH, free T3, free T4, anti-thyroperoxidase and anti-thyroglobulin antibodies, homocysteine, apelin and irisin levels were measured in all study subjects. Thyroid and carotid ultrasound examinations were performed. The subclinical hypothyroid group was reevaluated after 12-weeks of levothyroxine therapy when they became euthyroid. Results: Clinical characteristics of the patient and control group were similar. Glucose, insulin and HOMA levels, lipid parameters and free T3 were similar between the two groups.. Serum homocystein was higher and apelin was lower in patients with SCH, but irisin levels were similar between the two groups. While thyroid volume was lower, carotid IMT was significantly greater in patients with SCH (pCarotidIMT:0,01). After 12-weeks of levothyroxine therapy, all the studied parameters remained unchanged except, serum freeT4, TSH, homocystein and apelin. While homocystein decreased (p: 0,001), apelin increased significantly (p = 0,049). In multivariate analysis, low apelin levels significantly contributed to carotid IMT (p = 0,041). Conclusions: Apelin-APJ system may play a role in vascular and cardiac dysfunction in patients with SCH and treatment of this condition may improve the risk of cardiovascular disease.
机译:目的:在这项研究中,我们旨在评估亚临床甲状腺功能减退症(SCH)的亚临床甲状腺功能减退(SCH)患者在左甲状腺素治疗后是否变为甲状腺功能正常,以及这些脂肪因子与动脉粥样硬化标志物如血清同型半胱氨酸水平和颈动脉的相关性内膜中层厚度(IMT)。受试者和方法:该研究包括160例因桥本甲状腺炎而新诊断为亚临床甲状腺功能减退的患者和86例甲状腺功能正常的受试者。在所有研究对象中均测量了血清葡萄糖和脂质谱,胰岛素,HOMA,TSH,游离T3,游离T4,抗甲状腺素氧化酶和抗甲状腺球蛋白抗体,高半胱氨酸,阿珀林和鸢尾素水平。进行了甲状腺和颈动脉超声检查。亚临床甲状腺功能减退组在甲状腺功能亢进治疗12周后接受左甲状腺素治疗重新评估。结果:患者和对照组的临床特征相似。两组之间的血糖,胰岛素和HOMA水平,脂质参数和游离T3相似。SCH患者的血清高半胱氨酸较高,而apelin较低,但两组之间的虹膜素水平相似。尽管甲状腺体积较低,但SCH患者的颈动脉IMT明显更高(pCarotidIMT:0,01)。左甲状腺素治疗12周后,除血清游离T4,TSH,高半胱氨酸和apelin外,所有研究的参数均保持不变。高半胱氨酸减少(p:0,001),而apelin则明显增加(p = 0,049)。在多变量分析中,较低的apelin水平显着促成了颈动脉IMT(p = 0,041)。结论:Apelin-APJ系统可能在SCH患者的血管和心脏功能障碍中发挥作用,对此病的治疗可能会增加心血管疾病的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号